Xeris Biopharma Q2 Revenue Jumps 29% to $92M, Tightens 2026 Guidance to $385M–$390M
XERS sits 47% above its 52-week low of $5.25.
Summary
Xeris Biopharma reported Q2 2026 revenue of $92.1 million, a 29% increase year-over-year, and tightened full-year revenue guidance to $385–$390 million. Recorlev led growth with an 81% revenue jump, while a non-cash charge from a convertible notes exchange resulted in a net loss.
Key Events · Earnings and Guidance · XERS
-
Q2 Revenue Beats, Guidance Tightened
Total revenue reached $92.1 million, up 29% year-over-year, with net product revenue of $91.0 million (+34%). Full-year 2026 revenue guidance was tightened to $385–$390 million.
-
Recorlev Drives Growth
Recorlev net revenue surged 81% to $56.8 million, reflecting strong patient demand and commercial execution.
-
Non-Cash Charge Hits Net Income
A $31 million non-cash charge from the convertible notes exchange agreements led to a net loss of $31.1 million, though adjusted EBITDA was $19.3 million.
-
Patent Allowances Strengthen IP
The USPTO issued a Notice of Allowance for a new Keveyis patent extending protection through at least 2039, and granted a second patent for XP-8121.
Analysis · XERS · Life Sciences
A strong second quarter saw total revenue climb 29% to $92.1 million, fueled by an 81% surge in Recorlev sales. Confidence in the trajectory prompted management to tighten full-year 2026 revenue guidance to $385–$390 million. While a one-time non-cash charge of $31 million from the convertible notes exchange pushed the bottom line to a net loss, adjusted EBITDA improved to $19.3 million. The results, together with new patent allowances for Keveyis and XP-8121, reinforce both the commercial and pipeline narrative, though the net loss and recent insider selling warrant attention.
At the time of this filing, XERS was trading at $7.69 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.4B. The 52-week trading range was $5.25 to $10.08. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.